Serabelisib (INK1117,TAK-117) is a potent, selective PI3K p110α inhibitor with IC50 of 15 nM, displays >300-fold selectivity over p110β/γ/δ and mTOR.
Serabelisib (INK1117,TAK-117) inhibits AKT phosphorylation and growth in PIK3CA mutant breast cancer cells with IC50 of 2 uM, significantly suppresses B cell proliferation driven by anti-IgM alone but not by anti-IgM plus IL-4.
Serabelisib (INK1117,TAK-117) abrogates immune checkpoint mediated proliferation in peripheral T-cell lymphoma combined with alisertib.
